OA13170A - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. - Google Patents

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. Download PDF

Info

Publication number
OA13170A
OA13170A OA1200500329A OA1200500329A OA13170A OA 13170 A OA13170 A OA 13170A OA 1200500329 A OA1200500329 A OA 1200500329A OA 1200500329 A OA1200500329 A OA 1200500329A OA 13170 A OA13170 A OA 13170A
Authority
OA
OAPI
Prior art keywords
formula
compound
group
compounds
pyrazolo
Prior art date
Application number
OA1200500329A
Other languages
English (en)
French (fr)
Inventor
Maria Gabriella Brasca
Roberto D Alessio
Daniele Fancelli
Ron Ferguson
Achille Panzeri
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of OA13170A publication Critical patent/OA13170A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200500329A 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. OA13170A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22

Publications (1)

Publication Number Publication Date
OA13170A true OA13170A (en) 2006-12-13

Family

ID=33476970

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500329A OA13170A (en) 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.

Country Status (36)

Country Link
US (8) US7482354B2 (he)
EP (1) EP1636236B1 (he)
JP (1) JP5043432B2 (he)
KR (1) KR101084871B1 (he)
CN (2) CN102079746A (he)
AP (1) AP2064A (he)
AR (2) AR044543A1 (he)
AU (1) AU2004240772B2 (he)
BR (2) BRPI0410563B8 (he)
CA (1) CA2526578C (he)
CO (1) CO5721006A2 (he)
CR (1) CR8102A (he)
CY (1) CY1114708T1 (he)
DK (1) DK1636236T3 (he)
EA (1) EA010904B1 (he)
EC (1) ECSP056194A (he)
ES (1) ES2436524T3 (he)
GE (1) GEP20094664B (he)
HR (1) HRP20050967B8 (he)
IL (1) IL172046A (he)
IS (1) IS2939B (he)
ME (1) ME00142B (he)
MX (1) MXPA05012573A (he)
MY (1) MY142019A (he)
NO (1) NO334992B1 (he)
NZ (1) NZ543661A (he)
OA (1) OA13170A (he)
PL (1) PL1636236T3 (he)
PT (1) PT1636236E (he)
RS (2) RS52899B (he)
SI (1) SI1636236T1 (he)
TN (1) TNSN05298A1 (he)
TW (1) TWI349672B (he)
UA (1) UA80763C2 (he)
WO (1) WO2004104007A1 (he)
ZA (1) ZA200509486B (he)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2007213791A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
AU2007247112B2 (en) * 2006-05-09 2010-08-26 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
MX2009006613A (es) 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
ZA200904912B (en) * 2006-12-21 2010-09-29 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AU2008315048A1 (en) 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
JP5537439B2 (ja) * 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド 細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
EA020703B9 (ru) * 2008-06-26 2015-12-30 Ле Лаборатуар Сервье Пиразолохиназолины
EP2320903B1 (en) * 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
ES2532732T3 (es) 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
US8912194B2 (en) * 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CN102356083B (zh) * 2009-03-20 2014-10-15 内尔维阿诺医学科学有限公司 用于胸腺瘤治疗的激酶抑制剂的用途
WO2010122091A1 (en) 2009-04-22 2010-10-28 Boehringer Ingelheim International Gmbh Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
AR076784A1 (es) 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
CN102470136B (zh) * 2009-07-29 2013-12-25 内尔维阿诺医学科学有限公司 Plk 抑制剂的盐类
WO2011094545A2 (en) * 2010-01-28 2011-08-04 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
US9333205B2 (en) 2010-07-30 2016-05-10 Nerviano Medical Sciences S.R.L. Isoxazolo-quinazolines as modulators of protein kinase activity
EP2619181A1 (en) 2010-09-23 2013-07-31 Syngenta Participations AG Novel microbiocides
RU2621674C2 (ru) * 2010-10-25 2017-06-07 Г1 Терапьютикс Инк., Ингибиторы cdk
US8541576B2 (en) 2010-12-17 2013-09-24 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
JP5925808B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用
US8975267B2 (en) * 2011-01-26 2015-03-10 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CN103635230B (zh) 2011-05-12 2017-10-31 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
AR089776A1 (es) * 2012-01-23 2014-09-17 Boehringer Ingelheim Int 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
HUE043108T2 (hu) 2014-04-07 2019-07-29 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e]indolizinek
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN108348486A (zh) 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
CA3030054A1 (en) 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
WO2018086591A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
WO2019011715A1 (en) 2017-07-11 2019-01-17 Nerviano Medical Sciences S.R.L. PYRAZOLO-QUINAZOLINE DERIVATIVES AS INHIBITORS OF CHOLINE KINASE
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CN114423765A (zh) * 2019-09-05 2022-04-29 成都赛璟生物医药科技有限公司 异唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
CN116761806A (zh) * 2021-02-08 2023-09-15 南京明德新药研发有限公司 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
WO2023104178A1 (zh) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
OA12046A (en) 1999-08-12 2006-05-02 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents.
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
CA2417635C (en) 2000-08-11 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2004517840A (ja) 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
NZ527767A (en) 2001-01-26 2004-11-26 Pharmacia Italia S Chromane derivatives, process for their preparation and their use as antitumor agents
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2003013655A2 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
EP1432416B1 (en) 2001-09-26 2011-01-19 Pfizer Italia S.r.l. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
EP1476431A1 (en) 2002-02-19 2004-11-17 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
MX2009006613A (es) * 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.

Also Published As

Publication number Publication date
US7482354B2 (en) 2009-01-27
BRPI0410563B8 (pt) 2021-05-25
CN102079746A (zh) 2011-06-01
MEP25908A (en) 2010-06-10
JP5043432B2 (ja) 2012-10-10
NO20055496L (no) 2006-02-14
ECSP056194A (es) 2006-04-19
GEP20094664B (en) 2009-04-10
US20070185143A1 (en) 2007-08-09
EP1636236A1 (en) 2006-03-22
CA2526578A1 (en) 2004-12-02
AP2005003452A0 (en) 2005-12-31
ZA200509486B (en) 2008-09-25
MY142019A (en) 2010-08-16
US8541429B2 (en) 2013-09-24
US20090124605A1 (en) 2009-05-14
NO20055496D0 (no) 2005-11-21
US20190194214A1 (en) 2019-06-27
RS20050944A (en) 2008-06-05
BR122019010200B1 (pt) 2020-12-15
US8981089B2 (en) 2015-03-17
HRP20050967A2 (en) 2007-05-31
AP2064A (en) 2009-10-30
IL172046A (he) 2017-03-30
RS52899B (en) 2014-02-28
EA010904B1 (ru) 2008-12-30
NZ543661A (en) 2009-05-31
KR101084871B1 (ko) 2011-11-21
UA80763C2 (en) 2007-10-25
AR044543A1 (es) 2005-09-21
KR20060015294A (ko) 2006-02-16
SI1636236T1 (sl) 2014-01-31
US20170190714A1 (en) 2017-07-06
BR122019010200B8 (pt) 2021-07-27
NO334992B1 (no) 2014-08-18
JP2007502851A (ja) 2007-02-15
WO2004104007A1 (en) 2004-12-02
US10280176B2 (en) 2019-05-07
AU2004240772B2 (en) 2011-04-28
US20150158876A1 (en) 2015-06-11
HRP20050967B1 (hr) 2014-03-28
US9464090B2 (en) 2016-10-11
US20170050972A1 (en) 2017-02-23
IS8132A (is) 2005-11-18
AR102722A2 (es) 2017-03-22
PL1636236T3 (pl) 2014-02-28
ES2436524T3 (es) 2014-01-02
PT1636236E (pt) 2013-12-16
TNSN05298A1 (fr) 2007-07-10
US9637497B2 (en) 2017-05-02
CO5721006A2 (es) 2007-01-31
EP1636236B1 (en) 2013-10-09
HRP20050967B8 (hr) 2014-04-25
CR8102A (es) 2006-08-09
MXPA05012573A (es) 2006-02-22
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
TWI349672B (en) 2011-10-01
CN1826343A (zh) 2006-08-30
CA2526578C (en) 2012-01-24
BRPI0410563A (pt) 2006-06-20
IS2939B (is) 2016-03-15
BRPI0410563B1 (pt) 2020-12-01
DK1636236T3 (da) 2013-12-09
US20130338148A1 (en) 2013-12-19
US20210300935A1 (en) 2021-09-30
AU2004240772A1 (en) 2004-12-02
ME00142B (me) 2010-10-10
TW200505924A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
OA13170A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
KR101223826B1 (ko) 키나제 억제제로서의 치환된 피롤로-피라졸 유도체
JP6181862B2 (ja) ピラゾロピロリジン誘導体および疾患の処置におけるその使用
JP2005529850A (ja) 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
KR20150041787A (ko) 2,3-벤조디아제핀
EA028175B1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
WO2007071621A1 (en) Heteroarylpyrrolopyridinones active as kinase inhibitors